QL1706
Clinical trials for QL1706 explained in plain language.
Never miss a new study
Get alerted when new QL1706 trials appear
Sign up with your email to follow new studies for QL1706, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy may spare breast cancer patients from Heart-Harming drugs
Disease control Not yet recruitingThis study tests a new approach for people with early-stage triple-negative breast cancer. It combines an immunotherapy drug (QL1706) with chemotherapy before surgery. The key idea is to use scans and biopsies after the first part of treatment to see who responds well. Those who …
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 08:11 UTC
-
New drug cocktail aims to shrink esophageal tumors in First-Line fight
Disease control Not yet recruitingThis study tests a new drug called QL1706, which boosts the immune system to attack cancer cells, combined with two chemotherapy drugs (nab-paclitaxel and cisplatin) as the first treatment for people with advanced or metastatic esophageal squamous cell carcinoma. About 50 adults …
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Henan University of Science and Technology • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New combo aims to shrink colon tumors before surgery
Disease control Not yet recruitingThis study tests a new drug combination (iparomlimab and tuvonralimab, called QL1706) plus chemotherapy (XELOX) given before surgery to people with stage III colon cancer that is MSS/pMMR. The goal is to see if this treatment can completely eliminate the tumor by the time of surg…
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated May 22, 2026 13:53 UTC